The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence
Crossref DOI link: https://doi.org/10.1007/s40273-016-0419-7
Published Online: 2016-06-08
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sideris, Eleftherios
Corbett, Mark
Palmer, Stephen
Woolacott, Nerys
Bojke, Laura
Funding for this research was provided by:
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project number 13/169/01)
License valid from 2016-06-08